The CLL Tribune Q4 Reader Poll Results

March 25, 2016

December 2015-January 2016

During December 2015-January 2016, the CLL Society conducted a poll among readers of the second issue of The CLL Tribune. The survey included questions assessing participation and/or interest in clinical trials, types of treatment, if any, participation and/or interest in face-to-face support groups, as well as demographic information. 164 complete responses were received:

Average age – 66 (range 47-89)
20% Male, 80% Female
95% were patients; 5% were caregivers
99% of respondents expressed interested in participating in a face-to-face support group if one was available in their area

Twenty-seven percent of respondents are currently participating or have participated in one or more clinical trials in the past. Almost half would consider participating in a clinical trial in the future. Twenty percent have not yet received any treatment. [Figure 1]

Figure 1. Treatment Status

Thirty-four percent reported that they have been treated with chemotherapy or with chemo-immunotherapy, such as FCR, BR, FR, PCR; chlorambucil with or without R or others or; any of these using the antibodies, obinutuzumab or ofatumumab instead of rituximab. Forty-one percent have not received any treatment yet. [Figure 2] One-quarter of respondents report being treated outside of a clinical trial with a novel agent, such as ibrutinib (Imbruvica) or idelalisib (Zydelig).